Skip to main content
. Author manuscript; available in PMC: 2016 Apr 25.
Published in final edited form as: Eur J Cancer. 2016 Feb 12;56:162–171. doi: 10.1016/j.ejca.2015.12.022

Fig. 1.

Fig. 1

Overall response rate of nab-paclitaxel/carboplatin (nab-PC) and solvent-based paclitaxel/carboplatin (sb-PC) on the basis of independent assessment in a randomized phase III clinical trial comparing nab-PC versus sb-PC in newly diagnosed advanced non-small cell lung cancer patients, in the intention-to-treat (ITT) population and by histology.